Developer docs
API playgroundTry for free, no card

Search company profiles

Upstream Bio

Full company profile

uuid00006x3

Namestring
Upstream Bio
Legal namestring
Upstream Bio, Inc.
Websiteurl
upstreambio.com
Company typeenum
Public
Founded yearint
2022
Descriptiontext

Upstream Bio is a clinical-stage biotechnology company developing verekitug (UPB-101), a recombinant fully human IgG1 monoclonal antibody that binds to and inhibits the thymic stromal lymphopoietin (TSLP) receptor. TSLP is positioned upstream in the inflammatory signaling cascade, so receptor inhibition disrupts activation of multiple downstream mediators (IL-4, IL-5, IL-13, IL-17, IgE) implicated in chronic respiratory inflammation. Verekitug is the only known clinical-stage mAb targeting the TSLP receptor and is being evaluated in three indications: severe asthma (Phase 2 VALIANT, 56% reduction in annualized exacerbation rate), chronic rhinosinusitis with nasal polyps or CRSwNP (Phase 2 VIBRANT, approximately 80% of participants achieving clinically meaningful nasal polyp improvements), and chronic obstructive pulmonary disease or COPD (Phase 2 VENTURE). Phase 3 registrational trials in CRSwNP and severe asthma are planned to initiate in Q1 2027.

The company is headquartered in Waltham, Massachusetts (890 Winter Street, Suite 200), was originally founded as Seeker Biologics, and went public on NASDAQ under the ticker UPB in 2024 after raising approximately $293 million in its IPO. Prior to the IPO, Upstream Bio raised $200 million in Series A funding in June 2022 (led by Maruho and OrbiMed) and $200 million in Series B funding in June 2023 (led by Venrock Healthcare Capital Partners and Enavate Sciences). The company has raised an additional $150 million via an at-the-market equity sales agreement with Leerink Partners entered into in March 2026. As of Q4 2025, Upstream Bio held $341.5 million in cash, which management expects will fund planned operations through 2027.

Upstream Bio's revenue model is contingent on future commercialization of verekitug following regulatory approval. The company currently generates no product revenue. Once approved, verekitug — a subcutaneous biologic dosed quarterly at 100mg — is expected to be distributed through specialty pharmacies and hospital channels, targeting pulmonologists, allergists, and ENT specialists who treat severe asthma, CRSwNP, and COPD patients. With approximately 350 million asthma patients worldwide (5–10% with severe disease), up to 4% of the general population affected by CRSwNP (40% uncontrolled), and COPD as the fourth leading cause of death globally, the addressable patient population is substantial. Strategic clinical collaboration with Maruho Co., Ltd. supports ex-US clinical execution, particularly in Japan.

Short descriptiontext

Upstream Bio is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody targeting the TSLP receptor for severe asthma, CRSwNP, and COPD. The publicly traded (NASDAQ: UPB) Waltham-based biotech expects to initiate Phase 3 trials in Q1 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapeutics, respiratory disease treatment, TSLP receptor antagonist, inflammatory disease pipeline, clinical-stage biotechnology
Industry1 code
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Product Sales (post-approval)
TypeOne Time License
Description

Upstream Bio is a clinical-stage biotech with no current approved products. The company's revenue model is expected to be derived from the commercialization of verekitug and potentially other pipeline candidates following regulatory approval. Once approved, the company will generate revenue through prescription drug sales for severe asthma, CRSwNP, and COPD.

upstreambio.com
2At-the-Market (ATM) Equity Offering
TypeSubscription Recurring
Description

Upstream Bio entered into a $150 million at-the-market sales agreement with Leerink Partners to raise capital through equity sales in the public market, supplementing cash reserves to fund clinical development operations.

in.investing.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1No approved products yet — pricing not established.
ModelOtherBilling cadenceOther
Notes

The company is in Phase 2/Phase 3 development stage. No commercial pricing available.

upstreambio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Verekitug (UPB-101)
Description

Novel recombinant fully human IgG1 monoclonal antibody targeting the TSLP receptor for treatment of severe respiratory diseases including asthma, CRSwNP, and COPD

upstreambio.com
Core offering1 text field

Upstream Bio is a clinical-stage biotechnology company developing verekitug (UPB-101), a novel recombinant fully human IgG1 monoclonal antibody that binds to and inhibits the TSLP (thymic stromal lymphopoietin) receptor. The company is advancing verekitug through Phase 2 and Phase 3 clinical trials as a potential treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Verekitug is the only known clinical-stage monoclonal antibody that potently targets and inhibits the TSLP receptor.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 56% reduction in annualized asthma exacerbation rate at 100mg q12w dosing in Phase 2 VALIANT trial (p<0.05)
+5 more records
Product overview1 text field

Upstream Bio is a clinical-stage biotechnology company developing verekitug (UPB-101), a novel fully human IgG1 monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor. Verekitug is the only known clinical-stage monoclonal antibody that potently targets and inhibits the TSLP receptor, positioned upstream in inflammatory signaling cascades. The company has advanced verekitug into multiple Phase 2 clinical trials across three respiratory indications: chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). The company's clinical trial portfolio includes completed VIBRANT trial (CRSwNP), completed VALIANT trial (severe asthma), ongoing VALOUR long-term extension trial, and ongoing VENTURE trial (COPD). Phase 3 registrational trials are planned to initiate in Q1 2027 for both CRSwNP and severe asthma.

Product and service1 record
1Verekitug (UPB-101)
CategoryMonoclonal Antibody Therapeutic
Description

Verekitug is a novel recombinant fully human IgG1 monoclonal antibody that binds to the TSLP receptor and inhibits pro-inflammatory signaling initiated by TSLP. It is being developed as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD), administered via quarterly subcutaneous dosing (100mg every 12 weeks).

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Maruho Co., Ltd.
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Maruho Co., Ltd. is Upstream Bio's clinical trial collaboration partner, specifically for conducting clinical trial activities as part of Upstream Bio's global research and development plan for verekitug. Maruho contributes to specified clinical trial activities in Japan and potentially other regions, supporting the global development strategy.

upstreambio.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Upstream Bio

Biopharmaceutical Therapeuticsupstreambio.com

Upstream Bio is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody targeting the TSLP receptor for severe asthma, CRSwNP, and COPD. The publicly traded (NASDAQ: UPB) Waltham-based biotech expects to initiate Phase 3 trials in Q1 2027.

What Upstream Bio does

Upstream Bio is a clinical-stage biotechnology company developing verekitug (UPB-101), a recombinant fully human IgG1 monoclonal antibody that binds to and inhibits the thymic stromal lymphopoietin (TSLP) receptor. TSLP is positioned upstream in the inflammatory signaling cascade, so receptor inhibition disrupts activation of multiple downstream mediators (IL-4, IL-5, IL-13, IL-17, IgE) implicated in chronic respiratory inflammation. Verekitug is the only known clinical-stage mAb targeting the TSLP receptor and is being evaluated in three indications: severe asthma (Phase 2 VALIANT, 56% reduction in annualized exacerbation rate), chronic rhinosinusitis with nasal polyps or CRSwNP (Phase 2 VIBRANT, approximately 80% of participants achieving clinically meaningful nasal polyp improvements), and chronic obstructive pulmonary disease or COPD (Phase 2 VENTURE). Phase 3 registrational trials in CRSwNP and severe asthma are planned to initiate in Q1 2027.

The company is headquartered in Waltham, Massachusetts (890 Winter Street, Suite 200), was originally founded as Seeker Biologics, and went public on NASDAQ under the ticker UPB in 2024 after raising approximately $293 million in its IPO. Prior to the IPO, Upstream Bio raised $200 million in Series A funding in June 2022 (led by Maruho and OrbiMed) and $200 million in Series B funding in June 2023 (led by Venrock Healthcare Capital Partners and Enavate Sciences). The company has raised an additional $150 million via an at-the-market equity sales agreement with Leerink Partners entered into in March 2026. As of Q4 2025, Upstream Bio held $341.5 million in cash, which management expects will fund planned operations through 2027.

Upstream Bio's revenue model is contingent on future commercialization of verekitug following regulatory approval. The company currently generates no product revenue. Once approved, verekitug — a subcutaneous biologic dosed quarterly at 100mg — is expected to be distributed through specialty pharmacies and hospital channels, targeting pulmonologists, allergists, and ENT specialists who treat severe asthma, CRSwNP, and COPD patients. With approximately 350 million asthma patients worldwide (5–10% with severe disease), up to 4% of the general population affected by CRSwNP (40% uncontrolled), and COPD as the fourth leading cause of death globally, the addressable patient population is substantial. Strategic clinical collaboration with Maruho Co., Ltd. supports ex-US clinical execution, particularly in Japan.

Upstream Bio firmographics

Firmographics
Name
Upstream Bio
Legal name
Upstream Bio, Inc.
Website
https://upstreambio.com
Company type
Public
Founded year
2022
Operating status
Operating
Headcount range
51–100 employees
Short description
Upstream Bio is a clinical-stage biotechnology company developing verekitug, a monoclonal antibody targeting the TSLP receptor for severe asthma, CRSwNP, and COPD. The publicly traded (NASDAQ: UPB) Waltham-based biotech expects to initiate Phase 3 trials in Q1 2027.
Ownership category
akta.pro rank

Upstream Bio industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAB
Recombinant Protein Therapeutics (enzymes, hormones, growth factors)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Monoclonal antibody therapeutics
  • Respiratory disease treatment
  • TSLP receptor antagonist
  • Inflammatory disease pipeline
  • Clinical-stage biotechnology

Where Upstream Bio is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Upstream Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pharmaceutical Product Sales (post-approval): Upstream Bio is a clinical-stage biotech with no current approved products. The company's revenue model is expected to be derived from the commercialization of verekitug and potentially other pipeline candidates following regulatory approval. Once approved, the company will generate revenue through prescription drug sales for severe asthma, CRSwNP, and COPD.
  2. At-the-Market (ATM) Equity Offering: Upstream Bio entered into a $150 million at-the-market sales agreement with Leerink Partners to raise capital through equity sales in the public market, supplementing cash reserves to fund clinical development operations.

Pricing tiers

ModelBillingPrice
OtherOtherNo approved products yet — pricing not established.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Upstream Bio product offering

Product offering

Core offering

Upstream Bio is a clinical-stage biotechnology company developing verekitug (UPB-101), a novel recombinant fully human IgG1 monoclonal antibody that binds to and inhibits the TSLP (thymic stromal lymphopoietin) receptor. The company is advancing verekitug through Phase 2 and Phase 3 clinical trials as a potential treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Verekitug is the only known clinical-stage monoclonal antibody that potently targets and inhibits the TSLP receptor.

Product overview

Upstream Bio is a clinical-stage biotechnology company developing verekitug (UPB-101), a novel fully human IgG1 monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor. Verekitug is the only known clinical-stage monoclonal antibody that potently targets and inhibits the TSLP receptor, positioned upstream in inflammatory signaling cascades. The company has advanced verekitug into multiple Phase 2 clinical trials across three respiratory indications: chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). The company's clinical trial portfolio includes completed VIBRANT trial (CRSwNP), completed VALIANT trial (severe asthma), ongoing VALOUR long-term extension trial, and ongoing VENTURE trial (COPD). Phase 3 registrational trials are planned to initiate in Q1 2027 for both CRSwNP and severe asthma.

Differentiator

Problem solved

Functional benefit

Brands

  • Verekitug (UPB-101): Novel recombinant fully human IgG1 monoclonal antibody targeting the TSLP receptor for treatment of severe respiratory diseases including asthma, CRSwNP, and COPD

Products and services

  • Verekitug (UPB-101) Verekitug is a novel recombinant fully human IgG1 monoclonal antibody that binds to the TSLP receptor and inhibits pro-inflammatory signaling initiated by TSLP. It is being developed as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD), administered via quarterly subcutaneous dosing (100mg every 12 weeks).

Quantifiable outcome

  • 56% reduction in annualized asthma exacerbation rate at 100mg q12w dosing in Phase 2 VALIANT trial (p<0.05)
  • +5 more outcomes

Companies that use Upstream Bio

Customer profile

Segments3 records

Ideal customer profiles2 records

Upstream Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Upstream Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Maruho Co., Ltd.coreStrategic or Co-development PartnerMaruho Co., Ltd. is Upstream Bio's clinical trial collaboration partner, specifically for conducting clinical trial activities as part of Upstream Bio's global research and development plan for verekitug. Maruho contributes to specified clinical trial activities in Japan and potentially other regions, supporting the global development strategy.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Upstream Bio competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Upstream Bio social profiles

Digital presence

Upstream Bio compliance and trust

Trust signal

Compliance3 records

Upstream Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Upstream Bio leadership team

Management profile

Number of profiles

Profiles20 records

Upstream Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Upstream Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Upstream Bio

What does Upstream Bio do?

Upstream Bio is a clinical-stage biotechnology company developing verekitug (UPB-101), a novel recombinant fully human IgG1 monoclonal antibody that binds to and inhibits the TSLP (thymic stromal lymphopoietin) receptor. The company is advancing verekitug through Phase 2 and Phase 3 clinical trials as a potential treatment for chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and chronic obstructive pulmonary disease (COPD). Verekitug is the only known clinical-stage monoclonal antibody that potently targets and inhibits the TSLP receptor.

Is Upstream Bio a public or private company?

Upstream Bio is a public company. It is classified as public and is currently operating.

When was Upstream Bio founded?

Upstream Bio was founded in 2022. It employs 51 to 100 people.

Where is Upstream Bio based?

Upstream Bio is headquartered in Waltham, United States, in the North America region.

How does Upstream Bio make money?

Two revenue lines are on record. Pharmaceutical Product Sales (post-approval) is the primary driver. The others are at-the-Market (ATM) Equity Offering.

Does Upstream Bio have an API?

No public API is recorded for Upstream Bio.

What industry is Upstream Bio in?

Upstream Bio's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAAAB, Recombinant Protein Therapeutics (enzymes, hormones, growth factors). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewHC Wainwright & Co. maintains Upstream Bio at Buy, lowers price target to $18 from $36HC Wainwright & Co. maintained Upstream Bio at Buy and lowered its price target to $18 from $36, a 50% cut. The target implies a 432.5% upside from the Nov 10 close of $3.38.YahooUpstream Bio, Inc. (UPB) Reports Q3 Loss, Lags Revenue EstimatesUpstream Bio reported a Q3 loss of $0.75 per share, missing the consensus estimate of $0.67, and revenues of $0.4 million, down 49.16% from the $0.68 million estimate. The stock has fallen 86.8% year-to-date versus the S&P 500's 10.3% gain.American Banking and Market NewsHead-To-Head Review: Celularity (NASDAQ:CELU) versus Upstream Bio (NASDAQ:UPB)A head-to-head review compares Celularity and Upstream Bio on profitability, ownership, analyst ratings, and valuation. Upstream Bio has a stronger consensus rating and higher upside, while Celularity has higher revenue and earnings. The review concludes Celularity beats Upstream Bio on 7 of 13 factors.MarketBeatUpstream Bio (UPB) Expected to Release Earnings on WednesdayUpstream Bio is expected to report Q3 2026 earnings on Wednesday, with analysts projecting a loss of $0.7286 per share and revenue of $0.52 million. The company previously beat estimates with a $0.73 loss and $0.77 million revenue. Analysts have a consensus 'Hold' rating with a target price of $29.67.American Banking and Market NewsAnalyzing Upstream Bio (NASDAQ:UPB) & Organogenesis (NASDAQ:ORGO)Organogenesis has higher revenue ($564.17M vs $2.85M) and earnings than Upstream Bio, but Upstream Bio has a stronger analyst consensus and higher upside. Organogenesis beats Upstream Bio on 8 of 13 factors, including profitability and valuation.MarketBeatUpstream Bio, Inc. (NASDAQ:UPB) Stock Rated "Hold" by Wall Street BrokeragesUpstream Bio's stock received an average "Hold" rating from seven brokerages, with an average 12-month target of $29.67. The company reported Q2 EPS of -$0.73, beating estimates, and revenue of $0.77 million. Analysts expect -$2.84 EPS for the current year.Markets DailyReviewing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)Upstream Bio beats Keros Therapeutics on 7 of 13 factors, including higher revenue and a lower price-to-earnings ratio. Analysts rate Upstream Bio more favorably with a higher consensus target price, implying greater upside.American Banking and Market NewsReviewing Upstream Bio (NASDAQ:UPB) & Keros Therapeutics (NASDAQ:KROS)Keros Therapeutics and Upstream Bio are compared on profitability, institutional ownership, and analyst ratings. Upstream Bio beats Keros on 7 of 13 factors, with a higher consensus price target and upside. Analysts favor Upstream Bio, citing its stronger rating and higher probable upside.American Banking and Market News391,762 Shares in Upstream Bio, Inc. $UPB Bought by Bank of America Corp DEBank of America Corp DE bought 391,762 shares of Upstream Bio in Q2, valued at about $2.71 million. Analysts rate the stock a Hold with an average target of $29.67, and the company reported a loss of $0.73 per share for the quarter.TradingViewNews by MarketWatch on TradingView, 2026-09-21Mark Hulbert argues that tax-loss selling in Q4 will depress 20 stocks, which often rebound in January. Past lists gained 39.6% and 20.9% from Q4 lows to January highs, versus 6.6% and 7.2% for the S&P 500. He suggests placing buy limit orders below current prices.